

# From bench to bedside: emerging approaches in cancer drug discovery

## DAY 1 - OCTOBER 28th

Time (ET)	Session	
11:00 AM	<b>Fully human model systems to study personalized antitumor immune responses in lung cancer</b> Heidi Haikala, PhD, University of Helsinki & Tampere University	
11:35 AM	<b>Cell-based assays for immuno-oncology</b> Ethan Shelkey, PhD, R&D Scientist, Lonza	
12:20 PM	<b>KLIPP: precision targeting of cancer with CRISPR</b> Mats Ljungman, PhD, University of Michigan Medical School	
1:15 PM	<b>Revolutionizing immune cell therapy and antibody discovery with functional single-cell analysis</b> Edward Han, PhD, Product Manager, Bruker Cellular Analysis	
1:35 PM	<b>Cyclic peptides as therapeutic modalities</b> Min Xue, PhD, Associate Professor, Icahn School of Medicine at Mount Sinai	
2:35 PM	<b>Strategic use of CDX models in emerging IO therapies</b> Kiel Peck, PhD, Director, Scientific Operations, Crown Bioscience	
3:00 PM	<b>Enabling extracellular vesicle technologies for cancer diagnosis and treatment</b> Yong Zeng, PhD, Associate Professor, University of Florida	

## DAY 2 - OCTOBER 29th

Time (ET)	Session	
11:00 AM	<b>Pan-cancer N-glycoproteomic atlas of patient-derived xenografts uncovers FAT2 as a therapeutic target for head and neck cancers</b> Thomas Kislinger, PhD, Professor, University of Toronto	
11:45 AM	<b>Precision incubation: enabling emerging drug discovery through environmental control</b> Derek Sokolowski, MSL, Product Manager, Cell Culture, PHC Corporation of North America	
12:20 PM	<b>AI-driven high-throughput drug screening on patient-derived tumor organoids</b> Christophe Deben, PhD, Professor, University of Antwerp	
1:00 PM	<b>Drug discovery 2.0: integrating high-fidelity 3D cancer models at scale using RASTRUM</b> Sean Porazinski, PhD, Application Science Lead, Inventia Life Science	
1:20 PM	<b>Comprehensive characterization of the tumor microenvironment using a novel fully validated tissue biomarker discovery assay</b> Kirsteen Maclean, Ph.D, Principal Scientist, Pharma Services, NeoGenomics	
2:25 PM	<b>Next-generation personalized medicine proteomics and AI in clinical practice</b> Michal Harel, PhD, VP Translational Medicine, OncoHost	